# Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

> **NCT06334393** · PHASE1 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 150 (actual)

## Conditions studied

- Zika
- Zika Virus Infection

## Interventions

- **BIOLOGICAL:** VLA1601
- **BIOLOGICAL:** CpG 1018®
- **BIOLOGICAL:** 3M-052-AF

## Key facts

- **NCT ID:** NCT06334393
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-25
- **Primary completion:** 2025-04-21
- **Final completion:** 2026-02-27
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06334393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06334393, "Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06334393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*